A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors

被引：0
|
作者：
Yu, X. [1 ]
Zhang, J. [2 ]
Liu, R. [2 ]
Deng, Y. [3 ]
Cai, Y. [3 ]
Sun, Y. [4 ]
Dang, Q. [4 ]
Hong, W. [5 ]
Song, Z. [6 ]
Guo, S. [2 ,7 ]
Gao, S.
Su, W. [8 ]
Shi, M. [8 ]
Fan, S. [8 ]
Zhang, B. [8 ]
Pan, B. [8 ]
Ren, Y. [8 ]
Wang, J. [8 ]
Zhong, C. [8 ]
Ma, L. [8 ]
机构：
[1] Fudan Univ, Dept Pancreat Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou, Peoples R China
[4] Shandong Canc Hosp & Inst, Phase Clin Study Ctr 1, Jinan, Peoples R China
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Med Oncol, Canc Hosp, Hangzhou, Peoples R China
[6] Univ Chinese Acad Sci, Canc Hosp, Phase Clin Study Ward 1, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[7] Henan Univ Sci & Technol, Dept Med Oncol, Affiliated Hosp 1, Luoyang, Peoples R China
[8] HUTCHMED China Ltd, R&D, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77MO
引用
收藏
页码：S1496 / S1497
页数：2
相关论文
共 50 条
  • [31] An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
    Dudek, M. A.
    Zaslona, Z.
    Blaszczyk, R.
    Grzybowski, M. M.
    Rejczak, T.
    Cabaj, A.
    Dera, P.
    Lisiecki, K.
    Iwanowski, P.
    Charitos, T.
    Fung, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S495 - S495
  • [32] A Phase 1, First-in- human, Multicentre, Open-label, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumors
    Ulaner, Gary
    Juloori, Aditya
    Juneau, Daniel
    Schindler, Joanne
    Allan, Stephanie
    Jean-Louis, Lisa
    Nawinne, Moditha
    Mueller, Nancy
    Littlewood, Gillian
    Trigg, William
    Jacene, Heather
    Iagaru, Andrei
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [33] First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
    Lieu, C.
    Lenz, H. J.
    Kim, K. P.
    Sung, M. J.
    Kim, U-I.
    Meng, X.
    Benson, A. B., III
    ANNALS OF ONCOLOGY, 2024, 35 : S504 - S504
  • [34] A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
    Tibes, Raoul
    Fine, Gil
    Choy, Gavin
    Redkar, Sanjeev
    Taverna, Pietro
    Oganesian, Aram
    Sahai, Amarpal
    Azab, Mohammad
    Tolcher, Anthony W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 463 - 471
  • [35] A multicenter, open-label, dose-escalation, first-in-man study of MetAP2 inhibitor M8891 in patients with advanced solid tumours
    Carducci, M. A.
    Wang, D.
    Habermehl, C.
    Boedding, M.
    Rohdich, F.
    Stinchi, S.
    Karpenko, O.
    Gimmi, C.
    LoRusso, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S486 - S486
  • [36] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.
    Hollebecque, Antoine
    Soria, Jean-Charles
    Bahleda, Ratislav
    Lopez-Busto, Natividad
    Jacquet-Bescond, Anne
    Burbridge, Mike F.
    Valerie, Cattan
    Pauly, Jeanne
    Herranz, Maria
    Azaro, Analia
    Depil, Stephane
    Rodon, Jordi
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [37] A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
    Raoul Tibes
    Gil Fine
    Gavin Choy
    Sanjeev Redkar
    Pietro Taverna
    Aram Oganesian
    Amarpal Sahai
    Mohammad Azab
    Anthony W. Tolcher
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 463 - 471
  • [38] First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
    Sessa, Cristiana
    Shapiro, Geoffrey I.
    Bhalla, Kapil N.
    Britten, Carolyn
    Jacks, Karen S.
    Mita, Monica
    Papadimitrakopoulou, Vali
    Pluard, Tim
    Samuel, Thomas A.
    Akimov, Mikhail
    Quadt, Cornelia
    Fernandez-Ibarra, Cristina
    Lu, Hong
    Bailey, Stuart
    Chica, Sandra
    Banerji, Udai
    CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3671 - 3680
  • [39] A multicenter, open-label, dose-escalation (DE), first-in-human study of VEGFRs and CSF1R inhibitor SYHA1813 in patients (pts) with recurrent high-grade gliomas (HGG) or advanced solid tumors
    Li, W.
    Kang, Z.
    Li, S.
    Lin, Y.
    Li, Y.
    Mao, Y.
    Zhang, J.
    Lei, T.
    Wang, H.
    Su, Y.
    Yang, Y.
    Qiu, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S675 - S676
  • [40] Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
    Bendell, Johanna C.
    Hong, David S.
    Burris, Howard A., III
    Naing, Aung
    Jones, Suzanne F.
    Falchook, Gerald
    Bricmont, Patricia
    Elekes, Agnes
    Rock, Edwin P.
    Kurzrock, Razelle
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 125 - 130
12345